Author name: Leonardo Arias

But more than 300 hospitals didn’t participate in the CMS’ relief program, even though they faced financial disruption — and were more likely to be small and rural facilities, according to Health Affairs research.

Saol Therapeutics received a complete response letter for its pyruvate dehydrogenase complex deficiency treatment a week after the FDA unveiled its Rare Disease Evidence Principles program. On Dec. 18, in a Type A meeting, the biotech will attempt to convince the agency that its drug fits perfectly into the framework.

Virginia Tenpenny will oversee the hospital operator’s community engagement initiatives, including its social and charitable investments, outreach and strategic partnerships.

Pfizer apparently had more in the tank after the high-profile battle to acquire Metsera earlier this fall. The company has licensed a new GLP-1 from YaoPharma.

Ryan Weispfenning has elected to take up the challenge of creating and leading the investor relations function at the planned new diabetes company.

TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech’s shares flying.

Ben Newton, GE HealthCare’s global head of oncology, said the partnership will shift radiation therapy from a “one-size-fits-all” approach to a personalized method.

Structure’s aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech’s stock up nearly 103% as markets closed on Monday.

At the heart of the deal is Relation’s Lab-in-the-Loop platform, which uses AI models to improve understanding of diseases and guide clinical development programs.

For traditional approval, CAR T therapies will need to establish superiority over current standard treatments, including already-approved CAR T products.